Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis

Background: Multiple sclerosis (MS) is the most common immune-mediated demyelinating disease in younger adults. Patients with MS (PwMS) are vulnerable to the presence of potential drug-drug interactions (pDDIs) and potential drug-food interactions (pDFIs) as they take numerous medications to treat MS, associated symptoms and comorbidities. Knowledge about pDDIs and pDFIs can increase treatment success and reduce side effects. Objective: We aimed at determining the frequency and severity of pDDIs and pDFIs in PwMS, with regard to polypharmacy. Methods: In the cross-sectional study, we analysed pDDIs and pDFIs of 627 PwMS aged >= 18 years. Data collection was performed through patient record reviews, clinical examinations and structured patient interviews. pDDIs and pDFIs were identified using two DDI databases: Drugs.com Interactions Checker and Stockley's Interactions Checker. Results: We identified 2587 pDDIs (counted with repetitions). Of 627 PwMS, 408 (65.1%) had >= 1 pDDI. Polypharmacy (concomitant use of >= 5 drugs) was found for 334 patients (53.3%). Patients with polypharmacy (Pw/P) were found to have a 15-fold higher likelihood of having >= 1 severe pDDI compared with patients without polypharmacy (Pw/oP) (OR: 14.920, p<0.001). The most frequently recorded severe pDDI was between citalopram and fingolimoc Regarding pDFIs, ibuprofen and alcohol was the most frequent severe pDFI. Conclusion: Pw/P were particularly at risk of severe pDDIs. Age and educational level were found to be factors associated with the occurrence of pDDIs, independent of the number of medications taken. Screening for pDDIs/pDFIs should be routinely done by the clinical physician to increase drug safety and reduce side effects.

Automated summary

This study aimed to determine the frequency and severity of potential drug-drug interactions (pDDIs) and potential drug-food interactions (pDFIs) in patients with multiple sclerosis (PwMS) who are taking multiple medications. The study found that patients with polypharmacy were particularly at risk of severe pDDIs.